positive

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

3 days ago

Bybit Lists Syndicate (SYND) as Appchain Revolution Accelerates

DUBAI, UAE, Oct. 27, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is listing Syndicate (SYND) to…

1 week ago

Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025

Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac RecoveryMENLO PARK, Calif.--(BUSINESS WIRE)--#TFX--Jupiter Endovascular,…

1 week ago

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

2 weeks ago

More than 2,000 Cyclists pedal for Rs. 33.6 Lakhs at the 3rd edition of HCL Cyclothon Chennai

The Cycling Federation of India (CFI) as the technical partner, oversaw event guidelines, rules, and regulatory compliance. The theme was…

3 weeks ago

Apollomics, Inc. Company Operational Continuity Update

October 13, 2025 21:22 ET  | Source: Apollomics Inc. FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc.…

3 weeks ago

Lamborghini SC63 aims to finish on a positive note in IMSA GTP finale at Petit Le Mans

Daniil Kvyat returns to the wheel of the #63 LMDh alongside Grosjean and Mortara at Road AtlantaSant’Agata Bolognese, 7 October…

4 weeks ago

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…

4 weeks ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

2 months ago

ICMIs Contact Center Expo 2025 Unveils Keynote Speakers

Event Takes Place October 27-30 in Orlando, FloridaSAN FRANCISCO--(BUSINESS WIRE)--ICMI’s Contact Center Expo, which brings contact center industry professionals together…

2 months ago